Showing results (231-240 of 472) with videos related to

Sort By:
Pageof 48
The Journal of Infectious Diseases|May 14, 2008
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up, Jens D Lundgren, Abdel Babiker, et al.
Clinical Trials (London, England)|October 8, 2013
Network meta-analysis of randomized clinical trials: reporting the proper summariesJing Zhang, Bradley P Carlin, James D Neaton, et al.
Controlled Clinical Trials|April 12, 2002
The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRITSean Emery, Donald I Abrams, David A Cooper, et al.
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|December 1, 1986
Relationship of blood pressure to coronary and stroke morbidity and mortality in clinical trials and epidemiological studiesS W MacMahon, J A Cutler, J D Neaton, et al.
Contemporary Clinical Trials Communications|July 18, 2019
Comparison of an ordinal endpoint to time-to-event, longitudinal, and binary endpoints for use in evaluating treatments for severe influenza requiring hospitalizationRoss L Peterson, David M Vock, Abdel Babiker, et al.
Archives of Internal Medicine|July 1, 1992
Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research GroupJ D Neaton, H Blackburn, D Jacobs, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 10, 1998
Acyclovir use and survival among human immunodeficiency virus-infected patients with CD4 cell counts of < 500/mm3. The Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA)R A Torres, J D Neaton, D N Wentworth, et al.
Clinical Trials (London, England)|June 16, 2006
The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) eraA Mocroft, J Neaton, J Bebchuk, et al.
The New England Journal of Medicine|April 2, 2003
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarctionBertram Pitt, Willem Remme, Faiez Zannad, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 22, 2019
Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4+ Counts > 500 Cells/mm3: Findings From the Strategic Timing of AntiRetroviral Therapy (START) TrialJeffrey A Boatman, Jason V Baker, Sean Emery, et al.
Pageof 48